Clay B. Siegall Purchases 66,057 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 66,057 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was purchased at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the acquisition, the chief executive officer now owns 485,693 shares in the company, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Immunome Stock Performance

Immunome stock opened at $11.53 on Wednesday. Immunome, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $30.96. The stock’s 50 day simple moving average is $12.49 and its two-hundred day simple moving average is $13.55. The stock has a market cap of $719.70 million, a price-to-earnings ratio of -1.42 and a beta of 1.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Arizona State Retirement System raised its holdings in Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares in the last quarter. Clear Creek Financial Management LLC grew its position in shares of Immunome by 18.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after buying an additional 4,035 shares during the period. AQR Capital Management LLC increased its stake in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after acquiring an additional 4,129 shares in the last quarter. Cerity Partners LLC lifted its position in Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock valued at $776,000 after acquiring an additional 5,043 shares during the period. Finally, Quest Partners LLC bought a new stake in Immunome during the second quarter worth about $81,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

IMNM has been the subject of a number of analyst reports. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Stephens started coverage on Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, Piper Sandler decreased their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has an average rating of “Buy” and an average target price of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.